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Dendritic cells (DCs) play an important role in connecting innate and adaptive immunity.Thus, DCs have been regarded as amajor
target for the development of immunomodulators. In this study, we examined the effect of dextromethorphan (DXM), a common
cough suppressant with a high safety profile, on the activation and function of DCs. In the presence of DXM, the LPS-induced
expression of the costimulatory molecules in murine bone marrow-derived dendritic cells (BMDCs) was significantly suppressed.
In addition,DXM treatment reduced the production of reactive oxygen species (ROS), proinflammatory cytokines, and chemokines
inmaturing BMDCs that were activated by LPS.Therefore, DXM abrogated the ability of LPS-stimulated DCs to induce Ag-specific
T-cell activation, as determined by their decreased proliferation and IFN-𝛾 secretion in mixed leukocyte cultures. Moreover, the
inhibition of LPS-inducedMAPK activation andNF-𝜅B translocationmay contribute to the suppressive effect of DXMon BMDCs.
Remarkably, DXMdecreased the LPS-induced surface expression of CD80, CD83, andHLA-DR and the secretion of IL-6 and IL-12
in human monocyte-derived dendritic cells (MDDCs).These findings provide a new insight into the impact of DXM treatment on
DCs and suggest that DXM has the potential to be used in treating DC-related acute and chronic diseases.
1. Introduction
Dendritic cells (DCs), a highly specialized type of bone
marrow-derived leukocytes that are important for the initi-
ation of T-cell responses, link innate and adaptive immunity.
They are present in different stages of maturation in the
circulation as well as in lymphoid and nonlymphoid organs.
DCs reside in an immature form in nonlymphoid tissues,
where they act as sentinels [1–3]. After they capture and
process antigens in peripheral nonlymphoid tissues, DCs
migrate through afferent lymph to the T-cell-dependent areas
of secondary lymphoid organs (e.g., lymph nodes), where
they activate naive T-cell responses and undergo phenotypic
and functional changes (i.e., maturation). The immunostim-
ulatory properties of mature DCs include increased surface
expression of major histocompatibility complexes (MHCs)
with Ag-peptides and costimulatory molecules (e.g., CD40,
CD80), increased secretion of cytokines and chemokines,
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and reduced Ag uptake [4, 5]. While mature DCs can
potently initiate primary T-cell-mediated immune responses,
immature DCs stimulate T-cell responses only weakly ormay
even promote the generation of regulatory T (Treg) cells [6].
Because pharmacological modulation of DC activation
prevents the development of several T-cell-mediated diseases
[7], DCs may represent a new therapeutic approach for
treating harmful immune responses such as hypersensitivity
reactions and autoimmunity [8, 9]. Notably, the clinical
efficacy of corticosteroids and other antirheumatic drugs,
such as gold sodium thiomalate, leflunomide, mycophenolic
acid, and valproic acid, may be due to their significant
disruption of DC function [10–15].
Dextromethorphan (d-3-methoxy-17-methylmorphinan,
abbreviated DXM), a dextrorotatory morphinan, is
widely and clinically used as an antitussive. There is an
increasing evidence that DXM has anti-inflammatory
and immunomodulatory effects. DXM protects mice
against lipopolysaccharide/GalN-induced endotoxemia
and liver damage; the mechanism of protection may
involve faster TNF-𝛼 clearance, decreased superoxide
production, and decreased expression of genes associated
with inflammation and hepatocellular death [16]. In addition,
DXM prevents moderate experimental autoimmune
encephalomyelitis by inhibiting the NOX2-mediated
production of ROS and decreasing the infiltration of
monocytes and lymphocytes into the spinal cord [17]. DXM
reduces Group A Streptococcal (GAS)-induced systemic
inflammatory responses and organ injury in mice [18].
Furthermore, DXM reduces cytokine and superoxide
production in macrophages by inhibiting NAPDH oxidase,
resulting in decreased atherosclerosis and neointima in
mice [19]. DXM attenuates oxidative stress and inflammation
markers in habitual smokers [20]. Because the cellular targets
of DXM in the immune system have yet to be studied, the role
of DXM in the cellular maturation and immunoregulatory
activity of DCs is an open question.
In this study, we examined the potential effects of DXM
on the maturation and functional properties of DCs. We
found that DXM inhibited the LPS-induced functional mat-
uration of murine BMDCs and human MDDCs. In addi-
tion, DXMdownregulated the LPS-inducedMAPK signaling
pathways (ERK1/2, JNK, and p38 MAPK), I𝜅B expression,
and NF-𝜅Bp65 nuclear translocation. Taken together, these
results suggest that DXM manipulates the immunostimula-
tory properties of DC and may have important applications
against harmful immune responses such as chronic inflam-
mation, autoimmunity, and transplantation.
2. Material and Methods
2.1. Mice and Preparation of Bone Marrow-Derived Murine
DCs. Five- to eight-week-old specific pathogen-free female
C57BL/6 (H-2b) mice were purchased from the National
Laboratory Animal Center (Taipei, Taiwan) or the National
Cheng-Kung University (Tainan, Taiwan). OT-I TCR trans-
genic mice were purchased from Jackson Lab (Bar Harbor,
ME, USA), and OT-II TCR transgenic mice were provided
by Dr. Clifford Lowell (UCSF, San Francisco, CA, USA). All
mice were housed in the barrier facility at Taichung Veterans
General Hospital (Taichung, Taiwan) in accordance with
the Institutional Animal Care and Use Committee guide-
lines for animal experimentation. Murine bone marrow-
derived DCs were generated as previously described [21].
Briefly, femurs and tibias were aseptically removed from
mice. After the surrounding muscle tissue was removed, the
bones were placed in a 10mm dish with 70% alcohol for
1min, washed twice with phosphate-buffered saline (PBS),
and transferred into a fresh dish with RPMI 1640 medium.
Both ends of the bones were cut with scissors, and the
marrow was flushed with RPMI 1640 using a syringe and
a 25-gauge needle. The red cells were lysed with ammo-
nium chloride. Bone marrow cells (5–7 × 105 cells/mL)
were suspended in RPMI-1640 supplemented with 10% heat-
inactivated fetal bovine serum, 2mm L-glutamine, 100U/mL
penicillin, 100𝜇g/mL streptomycin, 5 × 105M 2-ME, 10mM
HEPES (pH 7.4), 20 ng/mL recombinant murine granulo-
cyte macrophage colony-stimulating factor (PeproTech), and
20 ng/mL recombinant murine IL-4 (PeproTech). Cells were
placed in 6-well plates. The culture medium was changed
every 2 days, and nonadherent or loosely adherent cells were
harvested on day 7 and used as immature DCs. More than
80% of the cells expressed CD11c, as determined using flow
cytometry. CD11c+ DCs were further selected from BM cells
with CD11c (N418) microbeads (Miltenyi Biotec), according
to the manufacturer’s instructions, and these cells were used
for the experiments.The purity of the CD11c+ cells was >90%
(data not shown).
2.2. Generation of HumanMonocyte-Derived DCs. DCs were
prepared from peripheral blood monocytes (PBMCs) by
standard procedures. Briefly, peripheral blood was collected
from healthy volunteer donors, and PBMCs were isolated
from peripheral blood buffy coats by magnetic cell sorting
with anti-CD14 MicroBeads, per the manufacturer’s protocol
(Miltenyi Biotec). The purity of the CD14+ fraction was
always >90%, as assessed using flow cytometry. Purified
monocytes were seeded in 6-well plates and cultured in
complete medium ( RPMI 1640 (Gibco) containing 10%
FBS (Gibco)), recombinant human 80 ngmL−1 GM-CSF
(PeproTech), and 100 ngmL−1 IL-4 (PeproTech) to generate
immature DCs. Every two days, fresh medium containing
GM-CSF and IL-4 was added to the cells. After 7 days of cul-
ture, nonadherent or loosely adherent cells were harvested,
washed once with PBS, and used for the experiments.
2.3. Flow Cytometry Analysis. The expression of cell surface
molecules was quantified by flow cytometry as follows.
DXM hydrobromide hydrate was purchased from Sigma-
Aldrich, and a 12.5mM stock solution was made with PBS.
Aliquots of 2 × 105 immature BMDCs or MDDCs were
cultured in the presence or absence of DXM for 1 h and
then stimulated with 100 ng/mL Escherichia coli serotype
O26:B6 LPS (Sigma) or 100 ng/mL LPS plus 10 ng/mL IFN-𝛾
(PeproTech) for 18 h.The control group was treated with PBS
alone. After incubation, DCs were harvested and stained with
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the following antibodies for 45min on ice (1 𝜇g/mL diluted
in PBS/1.0% FCS (v/v)): FITC-conjugated anti-humanCD1a+
or anti-murine CD11c+; phycoerythrin (PE)-conjugated anti-
humanCD80+, anti-humanCD83+, anti-murine CD40, anti-
murine CD80, anti-murine CD86, anti-murine MHC class I,
anti-murine MHC class II or isotype-matched control mAbs
(all of the above from Biolegends); or PE-conjugated anti-
human HLA-DR (BD Pharmingen). After washing with PBS,
the cells were analyzed in a FACSCalibur flow cytometer (BD
Biosciences), and the data were analyzed using WINMDI
software (Scripps, La Jolla, CA, USA).
2.4. Cytokine Assay. Supernatants were collected from DCs
(1 × 106/mL) propagated in the presence or absence of DXM
for 1 h. The cells were then stimulated with 100 ng/mL LPS
or 100 ng/mL LPS plus 10 ng/mL IFN-𝛾 or other TLR lig-
ands, including Pam3CSK4 (5 𝜇g/mL, TLR1/TLR2), PolyI:C
(250𝜇g/mL, TLR3), flagellin (500 ng/mL, TLR5), and CpG
ODN 1826 (200 nM TLR-9) (all from InvivoGen) for 18 h
(6 h for TNF-alpha and RANTES). The control group was
treated with PBS alone. After incubation, cytokine and
chemokine production in DC supernatants was determined
using sandwich ELISA assays, according to the manufac-
turer’s specifications (PeproTech).
2.5. Measurement of Reactive Oxygen Species (ROS).
ROS generation was measured after staining the cells
with the oxidative sensitive dye 5-(and-6)-carboxy-2󸀠,7󸀠-
dichlorodihydrofluorescein diacetate (DCFDA, Molecular
Probes). For this assay, DC cells at a density of 3 ×
105 cells/mL were cultured in the presence or absence of
DXM (50𝜇M) for 1 h followed by stimulation with 100 ng/mL
LPS. The control group was treated with PBS alone. After
LPS stimulation for 6 h, the medium was removed, and
culture medium containing 5 𝜇M DCFDA was added under
low-light conditions. The cells were incubated for 30min
at 37∘C, and the amount of ROS was analyzed by flow
cytometry as described above.
2.6. DXM Cytotoxicity Assay. To determine cell viabil-
ity and apoptosis, murine BMDCs and human MDDCs
(2× 105 cells/mL) were cultured in the presence or absence
of DXM for 1 h and stimulated with 100 ng/mL LPS for
18 h. The control group was treated with PBS alone. Cell
viability was determined using the CCK-8 colorimetric assay
according to the manufacturer’s instructions (Sigma). To
detect apoptosis, cell death was measured by flow cytometry
using a phycoerythrin-conjugated Annexin V detection kit-I
(BioVision) per the manufacturer’s protocol. Flow cytometry
was performed as described above by gating on 2 × 104
CD11c+ DC cells per sample.
2.7. OVA-Specific T-Cell Activation. The protocol was modi-
fied from our previous report [22]. Briefly, purified DCs were
pulsed with 2 𝜇g/mL OVA
257−264
(OVAP
1
) or OVA
323−339
(OVAP
2
) (synthesized by Echo Chemical Co., Taiwan) and
incubated with LPS (100 ng/mL), DXM (50𝜇M), or LPS plus
DXM for 18 h. After incubation, the cells were harvested
and washed with PBS. OVAP
1
specific CD8+ T cells and
OVAP
2
specific CD4+ T cells were positively enriched from
the spleens of OT-1 andOT-2mice using the EasySepMurine
CD8a or CD4 positive selection kits, respectively, according
to the manufacturer’s protocols (stem cells). The cells were
more than 90% pure, as determined by flow cytometry with
FITC-conjugated anti-CD4 and CD8 mAbs (Biolegends).
Purified T cells (2 × 105) and different treated DCs were
added at various DC : T-cell ratios to 96-well round-bottom
plates. After 3 days, T-cell proliferation was measured. [3H]
thymidine (1𝜇Ci; GE Healthcare) was added to the culture,
and after an overnight incubation period, the incorporated
[3H] thymidine was quantified by liquid scintillation count-
ing (𝛽-Counter; Beckman). In addition, supernatants from
the DC—OT-I/OT-II cultures were collected after 3 days,
and their IFN-𝛾 levels were measured using an ELISA kit
(eBioscience).
2.8. Preparation of Nuclear Extracts and Western Blot Anal-
ysis. Briefly, purified DCs were cultured in the presence
or absence of 50𝜇M DXM for 1 h and stimulated with
LPS (100 ng/mL). Whole-cell lysates were prepared at the
indicated time points, as described previously [23]. Nuclear
extracts were prepared using the NE-PER nuclear and cyto-
plasmic Extraction system (Pierce), per the manufacturer’s
instructions. All of the steps in the preparations included the
protease inhibitors leupeptin (Sigma-Aldrich) and aprotinin
(Sigma-Aldrich) at 10 𝜇g/mL. Protein concentrations were
determined using a BCA protein assay kit (Pierce). Protein
extractswere boiled, resolved by SDS-PAGEand electrotrans-
ferred to nitrocellulose membranes. After blocking in 10%
milk in TBS, the membranes were incubated with antibod-
ies for phospho-p38 (Thr180/Tyr182), p38, phospho-p42/44
(Thr202/Tyr204, 20G11), total p42/44 (137F5), phosphor-JNK
(81E11), JNK, anti-I𝜅B (56G8), anti- NF-𝜅B p65 (C22B4)
(all purchased from cell signaling) or anti-Lamin B (M-
20), anti-IDO Ab (mIDO-48) were purchased from Santa
Cruz Biotechnology. The membranes were then washed,
incubated with horseradish peroxidase-labeled secondary
Abs (Jackson ImmunoResearch, West Grove, PA, USA),
developed with enhanced chemoluminescence (Amersham),
and analyzed with the LAS3000 system (Fujifilm, Tokyo,
Japan). Densitometric analysis was performed with ImageJ
software (National Institute of Health, Bethesda, MD, USA).
2.9. Statistical Analysis. The results are expressed as the
mean ± SD. Statistical analyses were performed by one-way
ANOVA, followed by Tukey’s post-hoc test (Graphpad Prism
4.0, GraphPad Software). 𝑃 values < 0.05 were considered
statistically significant.
3. Results
3.1. DXM Affects the Expression of Cell Surface Molecules in
LPS-Stimulated Murine BMDCs. In the first series of experi-
ments, we investigated the effects of DXM on the maturation
of immature DCs. Immature BMDCs were cultured in the
presence of DXM (12.5, 25, 50, and 100 𝜇M) and then exposed
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to bacterial LPS which is a strong inducer of DC maturation.
In general, DC maturation is accompanied by the enhanced
expression of surface molecules, including costimulatory
molecules and major histocompatibility complex molecules
(MHC) that mediate adhesion with T cells by stabilizing
the DC/T cells contact zone. Consistent with previously
published data, the LPS stimulation of BMDCs resulted in the
significant upregulation of costimulatory molecules (CD80,
CD86 and CD40) and major histocompatibility complex
molecules (MHC class II, MHC class I) within 18 h. While
the DXM inhibition of LPS-induced maturation was dose-
dependent, the expression of CD80, CD86, CD40,MHC class
I, andMHC class II was significantly lower in the presence of
DXM than in untreatedmature BMDCs cells (Figure 1).These
effects were not due to an increase in the number of dead cells
(as determined by CCK-8 or flow cytometry with Annexin
V); there was no marked difference in the percentage of
dead cells in cultures containing 100 𝜇M DXM or PBS-
treated controls (Supplemental Figure 1(a) available online
at http://dx.doi.org/10.1155/2013/125643). These observations
suggested that DXM impaired LPS-induced DC phenotypic
maturation.
3.2. DXM Modulates Cytokine, Chemokine, and ROS Pro-
duction in LPS-Stimulated BMDCs. Mature DCs secrete
cytokines and chemokines that modulate inflammatory
responses and adaptive immunity [24]. We examined
whether DXM altered cytokine and chemokine secretion
in LPS-stimulated BMDCs. First, we examined changes in
the BMDC TNF-alpha production, which is a hallmark of
DC activation. TNF-alpha was quantified using ELISA for
supernatants that were collected from LPS-triggered BMDCs
propagated in the presence or absence of DXM. Figure 2
shows that unstimulated immature BMDCs did not produce
detectable levels of TNF-alpha. As expected, BMDCs started
producing a large amount of TNF-alpha after stimulation
with LPS, but DXM pretreatment led to dose-dependent
significant decreases in TNF-alpha production.The secretion
of other proinflammatory cytokines (e.g., IL-6, IL-12) and
chemokines (e.g., MCP-1, MIP-1 alpha, and RANTES) was
also inhibited by DXM. IL-12 production is an important
marker for DC maturation and can be used to select Th1-
dominant adjuvants (Figure 2). Additionally, increased levels
of reactive oxygen species (ROS) are involved in the activa-
tion of DCs by different stimuli, and antioxidants inhibit DC
activation [25]. To assess the potential intracellular mecha-
nisms for DXM inhibition of DC maturation, we analyzed
ROS levels in BMDCs pretreated with DXM and matured
with LPS, which is known to increase ROS in DCs [25].
As expected, ROS levels were increased following treatment
with LPS (Figure 3). However, treatment with DXM reduced
LPS-induced ROS in BMDCs. These results further suggest
thatDXMattenuates thematuration and immunostimulatory
activity of DCs activated by LPS.
3.3. DXM Inhibits the Ability of LPS-Stimulated BMDCs
to Stimulate OVA-Specific T-Cell Proliferation. Because the
critical function of mature DCs is to activate T-cell prolifer-
ation, we determined whether DXM-treated BMDCs could
induce antigen-specific CD4+ and CD8+ T-cell responses.
OVA
257−264
(OVAP
1
) orOVA
323−339
(OVAP
2
) peptide-loaded
immature BMDCs were preincubated in the presence or
absence of DXM, stimulated with LPS, and tested for their
ability to stimulate allogeneic OVA-specific CD4+ OT-II or
CD8+ OT-I T cells. T-cell proliferation was measured by [3H]
thymidine incorporation. Coculture with LPS-stimulated
BMDCs effectively enhanced CD4+ OT-II and CD8+ OT-I T-
cell proliferative responses, but this proliferation was reduced
byDXM(Figure 4). Because IFN-𝛾 is produced by activated T
cells, IFN-𝛾 in the culture supernatants was measured using
ELISA. As shown in Figure 5, DXM treatment reduced the
IFN-𝛾 produced by activated CD4+ and CD8+ T cells. Thus,
DXM attenuated the ability of DCs to activate Ag-specific T-
cell immune responses.
3.4. DXM Suppressed MAPK and NF-𝜅B Pathways in LPS-
Stimulated BMDCs. The activation of MAPKs and NF-𝜅B is
crucial for DC maturation and the inflammatory response
[26]. The LPS stimulation of TLR-4 signaling activates
MAPKs and NF-𝜅B signal pathways, resulting in DC matu-
ration [27, 28]. To explore the molecular mechanisms of the
DXM inhibitory effect, we determined whether MAPKs and
NF-𝜅B activation were altered by DXM in LPS-stimulated
BMDCs. DXM treatment blocked the phosphorylation of
MAPKs ERK, p38, and JNK but did not affect the level
of unphosphorylated proteins (Figure 5(a)). To determine
whether DXM decreased NF-𝜅B activation, the expression
of I𝜅B protein and nuclear translocation of NF-𝜅B p65 were
measured. I𝜅b is known to be an inhibitor of NF-𝜅b and can
form a complex with the NF-𝜅b, thereby preventing nuclear
translocation of NF-𝜅b. Under partial external stimulus such
as LPS, I𝜅B undergoes phosphorylation and degradation,
thereby unlockingNF-𝜅b and resulting in the nuclear translo-
cation of NF-𝜅b and the activation of related signaling
pathways. As shown in Figure 5, in LPS-stimulated BMDCs,
DXM treatment prevented downregulation of I𝜅B𝛼 protein
(Figure 5(a)) and decreased NF-𝜅B p65 nuclear localization
(Figure 5(b)). These results suggest that DXM inhibits LPS-
inducedDC activation, possibly by disrupting theMAPK and
NF-𝜅B pathways.
3.5. DXM Affects the Expression of Surface Markers and
Cytokine Secretion in Human Monocyte-Derived DCs
(MDDCs). In addition to murine BMDCs, we examined
whether DXM regulates LPS-induced surface molecule
expression and cytokine production in human MDDCs.
MDDCs were cultured in the presence or absence of DXM
for 1 h and then stimulated with LPS (100 ng/mL) plus IFN-𝛾
(10 ng/mL). Immature MDDCs stimulated with LPS plus
IFN-𝛾 released IL-6 and IL-12. The release of these cytokines
was suppressed by incubation with DXM (Figure 6(a)). We
also analyzed the effect of DXM on the expression of DC
surface activation markers. The LPS stimulation of MDDCs
resulted in the upregulation of CD80, CD83, and HLA-DR;
however, this upregulation was significantly inhibited by
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Figure 1: DXM reduces the expression of immunomodulatory cell surface markers in LPS-induced BMDCs. Immature BMDCs were
stimulated with 100 ng/mL LPS with or without DXM for 18 h. Control groups were treated with PBS alone. After incubation, the expression
of the surface markers CD40, CD80, CD86, MHC class I and MHC class II was analyzed by flow cytometry with fluorescently labeled Abs.
The gray-filled area represents staining with an isotype-matched control Ab. The geometric mean fluorescence intensity (GMFI) of LPS or
LPS+DXM is indicated. All data are representative of three independent experiments showing similar results.
DXM (Figure 6(b)). Also, these inhibited effects were not
due to cytotoxicity of DXM, because there were no marked
difference in the cell viability and percentage of Annexin
V+/dead cells in cultures containing DXM or PBS-treated
controls (Supplemental Figure 1(b)).
4. Discussion
Because DCs can initiate primary T-cell responses, they form
a crucial interface between innate and adaptive immunity.
Potential interference with this essential cell typemight affect
the pharmacological profile of an immunosuppressive drug
[10–14]. In this study, we examined the activity of DXM, a
widely used antitussive, on the immune function of DCs.
We showed that DXM interfered with DC maturation, as
measured using costimulatory molecules, cytokine, reactive
oxygen species (ROS), and stimulation of allogeneic T
cells. This is the first study to report that DXM has an
immunomodulatory effect on DCs.
The NF-𝜅B signaling pathway is critical for DC matu-
ration and cytokine production [28]. The NF-𝜅B signaling
pathway includes several importantmolecules such asNF-𝜅B,
I𝜅B, and I𝜅B kinase [29]. DXM inhibits LPS-induced I𝜅B𝛼
degradation and the nuclear translocation of p65 in human
endothelial cells [30]. MAPK signaling pathways have also
received attention as molecular targets for DC therapies [26–
28, 31, 32]. The minimal MAPK cascade consists of a three
kinase core where an MAP3K (MAP2K kinase) activates
a MAP2K (MAPK kinase) that activates an MAPK (ERK,
JNK, p38), resulting in the activation of NF-𝜅B pathways that
contribute to cell growth, survival, and antiapoptosis [33].
In this study, we showed that DXM decreased NF-𝜅B and
MAPK (ERK, p38, JNK) activation in LPS-treated BMDCs
(Figure 5), and this inhibitory effect was associated with DC
maturation.
Reactive oxygen species (ROS) are also known to have
important signaling properties, including activation of NF-
𝜅B and MAPK signaling in many cell types [34]. ROS
are also known to influence the production and secretion
of cytokines; after exposure to ROS, DCs more efficiently
present antigens [25]. Previous studies have shown that DXM
has antioxidant properties in many cell types [16, 19, 35–37].
In this study, we investigated whether DXM could affect ROS
formation during the process of LPS-stimulated dendritic
cell maturation. Our results confirmed that DXM inhibited
6 Clinical and Developmental Immunology
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Figure 2: DXM impaired the release of cytokines and chemokines from LPS-stimulated BMDCs. Immature BMDCs were stimulated with
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for TNF-alpha and RANTES), and cytokines and chemokines were quantified by ELISA. Data are presented as the means ± SD of samples
from three wells. Significant differences between DXM-treated and untreated LPS-activated BMDCs are shown with asterisks (∗𝑃 < 0.05,
∗∗
𝑃 < 0.01). All data are representative of three independent experiments.
0
64
Ev
en
ts
100 101 102 103 104
LPS
LPS + DXM (25𝜇M)
LPS + DXM (50𝜇M)
LPS + DXM (100𝜇M)
Control
(a)
0
20
40
60
80
100
120
Control LPS 25 50 100
M
FI
DXM (𝜇M)
∗
∗
(b)
Figure 3: ROS production in LPS-stimulated BMDCs was impaired by DXM. Immature BMDCs were stimulated with 100 ng/mL LPS with
or without DXM for 18 h.The control group was treated with PBS alone. After incubation, the cells were harvested, stained with DCFDA, and
analyzed by flow cytometry.Themean fluorescence intensities for ROS generation were tabulated.The data are represented as the mean ± SD
in triplicate tests. All data are representative of three independent experiments. Significant differences between DXM-treated and untreated
LPS-activated BMDCs are shown with asterisks (∗𝑃 < 0.05).
Clinical and Developmental Immunology 7
0
0.5
1
1.5
2
2.5
CP
M
 (×
10
4
)
∗
OT-II
0
0.5
1
1.5
2
2.5
CP
M
 (×
10
4
)
∗
OT-I
No T cells No T cells1 : 5 1 : 5
DC : T cells DC : T cells
(a)
0
2
4
6
8
10
No T cells
Control
LPS
IF
N
-𝛾
(n
g/
m
L) ∗
LPS + DXM
0
2
4
6
8
10
No T cells
IF
N
-𝛾
(n
g/
m
L)
∗
Control
LPS
LPS + DXM
1 : 5 1 : 5
DC : T cells DC : T cells
(b)
Figure 4: DXM inhibits Ag-specific T-cell activation by LPS-stimulated BMDCs. (a) Either OT-I CD8+ T cells or OT-II CD4+ T cells were
cocultured with BMDCs pulsed with OVA peptide and treated with PBS, LPS (100 ng/mL) + PBS, or LPS + DXM (50𝜇M) at the indicated
ratio of DC : T cells for 3 days. The cells were exposed to [3H]-thymidine for 18 h before cell-associated radioactivity was determined. (b)
Supernatants were collected from cultures after 4 days. IFN-𝛾 production was measured by ELISA. The data shown are the mean ± SD of
samples of three wells. Significant differences between DXM-treated and untreated LPS-activated BMDCs are shown with asterisks (∗𝑃 <
0.05). All data are representative of three independent experiments.
ROS production in LPS-stimulated BMDCs. Although the
underlying mechanism remains unclear, suppressed ROS
production due to the inhibition of NOX2, iNOS, or NADPH
oxidase expression and activity is possible [16, 19, 35, 38].
NOX2- and NADPH oxidase-deleted dendritic cells cannot
be induced to mature [39, 40]. Further investigation of the
influence and possible mechanism of action of DXM on
NOX2 and NADPH oxidase in dendritic cells is necessary.
Because activated DCs regulate T-cell responses, the type
of cytokines that they release may determine whether CD4+
T cells mature into Th1, Th2, Th17, or Treg cells [41]. IL-12
drives T helper type 1 (Th1) responses, whereas IL-4 promotes
Th2-type responses [42]. We observed that DXM signifi-
cantly inhibited LPS-induced IL-12 production in murine
and human DCs (Figures 2 and 6). In addition, we showed
that LPS-stimulated OVA peptide-pulsed BMDCs skewed
naive OT-II T cells toward IFN-𝛾-producing T cells, but OT-
II T cells stimulated with OVA-pulsed BMDCs exposed to
DXM produced lower levels of IFN-𝛾 (Figure 4). Because
IFN-𝛾 is a major product of Th1 cells [43], these results
suggest that DXM may be effective in several Th1-dominant
chronic inflammatory diseases, such as multiple sclerosis
(MS), diabetes, and rheumatoid arthritis (RA) [44].
The present study used the TLR-4 ligand LPS to stimulate
DC maturation. LPS induces strong Th1-like responses but
not Th2 immune responses [45]. We did not observe IL-4
expression in DCs after LPS stimulation (data not shown).
However, we cannot exclude the possibility that DXM affects
Th2 responses. Therefore, substances capable of stimulating
Th2 immune responses, such as dust mite allergens [46],
should be used in future investigations of the effects of DXM
on DC-mediatedTh2 responses.
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Figure 5: DXM inhibition of MAPK and NF-𝜅B activation in BMDCs. Immature BMDCs were stimulated with 100 ng/mL LPS with or
without DXM and lysed at the indicated time points. (a) The ERK, JNK, and p38 MAPK (native and phosphorylated) in whole cell lystes.
(b) I𝜅B𝛼 in whole-cell lystes and NF-𝜅B p65 in nuclear extracts as mentioned were determined by Western blot with antibodies. 𝛽-actin and
Lamin B loading controls are also shown to demonstrate relatively equal protein load across all lanes. The data are representative of three
independent experiments showing similar results.
We also found that DXM suppressed TNF-alpha expres-
sion when it was given before or after LPS stimulation (Sup-
plemental Figure 2), implying that the anti-inflammatory
and immunomodulatory effects of DXM could be used for
prevention or treatment purposes. Although LPS was the
main stimulus used for DC maturation in this study, we also
tested whether DXM couldmodulate the activation of imma-
ture BMDCs by other TLR ligands and applied Pam3CSK4,
PolyI:C, flagellin, and CpG ODN ligands for TLR1/TLR2,
TLR3, TLR5, and TLR9, respectively. The presence of each
substance resulted in the release of the proinflammatory
cytokine TNF-alpha. This release was completely inhibited
by 50 𝜇M of DXM (Supplemental Figure 3). Although the
mechanism of DXM interference with DC activation after
TLR ligand stimulation is not entirely clear, we suggest that
it may be related to the inhibitory effect of DXM on MAPK
and NF-𝜅B activation. NF-𝜅B is required for DCs to secrete
inflammatory cytokines after they are stimulatedwith various
TLR ligands [29]. Further investigation of the effect of DXM
on DC maturation through other non-TLR pathways such
asflt3 or c-kit ligands [47] or GM-CSF, IL-1𝛽, and IL-7
(FKGm17) cytokine stimuli is necessary.
Increased IDO expression in DCs can cause T-cell apop-
tosis via tryptophan starvation [48]. IDO expression in DCs
may be related to the differentiation of Treg cells [49, 50].
We found that DXM at 50𝜇M did not induce IDO expres-
sion or alter LPS-induced IDO expression (Supplemental
Figure 4(a)). Previous studies reported that IL-10 inhibits
effector T-cell responses and may induce Tr1 regulatory T-
cell differentiation [51, 52]. In this study, ELISA indicated
that no significant alteration in IL-10 expression was found
in BMDCs treated with or without LPS (Supplemental Figure
4(b)). Based on these results, we suggest that the T-cell-
inhibitory effect of DXM might occur via the suppression
of surface costimulatory receptor expression and cytokine
release. Further analysis ofmore immunomodulatory factors,
such as high levels of PD-L1 (programmed death-1 ligand),
retinoic acid (RA), TGF-beta, or other factors capable of
activating Treg differentiation or activation is required [53,
54].
The clinical dose of DXM for adult human is 60–
120mg/kg/day, and the peak concentration of DXM is about
8–16 𝜇M in serum after administration [55]. Another report
describes that the maximum concentration of DXM is about
0.8–9.64mg/kg (as high as 2 𝜇M) in the serum of neuro-
surgery patients; however, the concentration of DXM in brain
can be 68-fold higher than that in serum [56]. In our in
vitro study, we found that 12.5𝜇M–50 𝜇MDXMcan attenuate
the LPS-induced murine and human DC activation, which
dosage is possible in physiological condition, suggesting that
DXMmay have a potential to modulate DC function in vivo.
5. Conclusion
In summary, we provided evidence for a novel cellular target
of DXM in alloimmune responses in addition to its well-
known T-cell inhibitory capacity. Because of its potent effects
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Figure 6: DXM inhibited human MDDC activation. Immature MDDCs were treated with LPS (100 ng/mL) + IFN-𝛾 (10 ng/mL), LPS
(100 ng/mL) + IFN-𝛾 (10 ng/mL) + DXM (25, 50 𝜇M) for 18 h. The control group was treated with PBS alone. (a) Supernatants were collected
18 h later (TNF, 6 h), andTNF-alpha, IL-6, and IL-12 productionwasmeasured by ELISA.Data are presented as themean± SDof samples from
three wells. Significant differences between DXM-treated and untreated LPS + IFN-𝛾-activated DCs are shown with asterisks (∗𝑃 < 0.05).
(b) The expression of CD80, CD83, and HLA was determined by flow cytometry. All data were gated on CD1a+ cells. The gray-filled area
represents staining with an isotype-matched control Ab. The change of geometric mean fluorescence intensity in the LPS + IFN-𝛾 or LPS +
IFN-𝛾 + DXM samples is indicated. All data are representative of five independent experiments with cells from individual donors.
onDCs,DXMmay potentially prevent or treatDC-associated
chronic or acute immune diseases, such as MS, diabetes, and
RA [44]. Because DCs are important for the eradication of
tumors and pathogens [57–59], future clinical studies should
identify the risks associated with long-term DXM use.
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